mRNA-reprogrammed T Cells
Oncology (CAR-T/TCR-T therapies)
PreclinicalPlatform Development
Key Facts
Indication
Oncology (CAR-T/TCR-T therapies)
Phase
Preclinical
Status
Platform Development
Company
About Eterna Therapeutics
Eterna Therapeutics is focused on developing transformative mRNA-based cell engineering technologies to create a new generation of cellular medicines. The company's core platform enables precise, in vivo cell reprogramming and gene editing to treat a range of serious diseases. As a publicly traded entity, Eterna is advancing multiple preclinical programs while exploring strategic partnerships to accelerate its pipeline development.
View full company profile